Omnicell (NASDAQ:OMCL) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

Omnicell, Inc. (NASDAQ:OMCL) shares passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $35.06 and traded as low as $34.82. Omnicell shares last traded at $34.95, with a volume of 273,790 shares.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on OMCL shares. Wall Street Zen lowered Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Weiss Ratings downgraded Omnicell from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Wells Fargo & Company lowered their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $57.86.

Omnicell Stock Down 1.7%

The stock has a market cap of $1.61 billion, a P/E ratio of 36.41, a P/E/G ratio of 0.89 and a beta of 0.88. The company has a current ratio of 1.65, a quick ratio of 1.45 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average is $35.06 and its 200 day moving average is $38.49.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The company had revenue of $307.85 million during the quarter, compared to analysts’ expectations of $304.44 million. During the same period in the prior year, the company earned $0.51 earnings per share. The business’s quarterly revenue was down .9% compared to the same quarter last year. As a group, equities research analysts forecast that Omnicell, Inc. will post 1.64 EPS for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Omnicell during the 2nd quarter valued at $313,044,000. Dimensional Fund Advisors LP boosted its holdings in Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares during the period. Bank of America Corp DE boosted its holdings in Omnicell by 31.3% in the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the period. Boston Partners grew its position in Omnicell by 3.8% in the 3rd quarter. Boston Partners now owns 537,720 shares of the company’s stock worth $18,429,000 after purchasing an additional 19,561 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new stake in Omnicell in the 1st quarter worth $16,351,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.